369 related articles for article (PubMed ID: 17043158)
1. ANP differentially modulates marinobufagenin-induced sodium pump inhibition in kidney and aorta.
Fedorova OV; Agalakova NI; Morrell CH; Lakatta EG; Bagrov AY
Hypertension; 2006 Dec; 48(6):1160-8. PubMed ID: 17043158
[TBL] [Abstract][Full Text] [Related]
2. Effects of two putative endogenous digitalis-like factors, marinobufagenin and ouabain, on the Na+, K+-pump in human mesenteric arteries.
Bagrov AY; Fedorova OV
J Hypertens; 1998 Dec; 16(12 Pt 2):1953-8. PubMed ID: 9886882
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Na/K ATPase from rat aorta by two Na/K pump inhibitors, ouabain and marinobufagenin: evidence of interaction with different alpha-subunit isoforms.
Fedorova OV; Bagrov AY
Am J Hypertens; 1997 Aug; 10(8):929-35. PubMed ID: 9270089
[TBL] [Abstract][Full Text] [Related]
4. Age-associated increase in salt sensitivity is accompanied by a shift in the atrial natriuretic peptide modulation of the effect of marinobufagenin on renal and vascular sodium pump.
Fedorova OV; Kashkin VA; Zakharova IO; Lakatta EG; Bagrov AY
J Hypertens; 2012 Sep; 30(9):1817-26. PubMed ID: 22796708
[TBL] [Abstract][Full Text] [Related]
5. Intrahippocampal microinjection of an exquisitely low dose of ouabain mimics NaCl loading and stimulates a bufadienolide Na/K-ATPase inhibitor.
Fedorova OV; Zhuravin IA; Agalakova NI; Yamova LA; Talan MI; Lakatta EG; Bagrov AY
J Hypertens; 2007 Sep; 25(9):1834-44. PubMed ID: 17762648
[TBL] [Abstract][Full Text] [Related]
6. Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism.
Bagrov AY; Dmitrieva RI; Dorofeeva NA; Fedorova OV; Lopatin DA; Lakatta EG; Droy-Lefaix MT
J Hypertens; 2000 Feb; 18(2):209-15. PubMed ID: 10694190
[TBL] [Abstract][Full Text] [Related]
7. Phorbol diacetate potentiates na(+)-k(+) ATPase inhibition by a putative endogenous ligand, marinobufagenin.
Fedorova OV; Dorofeeva NA; Lopatin DA; Lakatta EG; Bagrov AY
Hypertension; 2002 Feb; 39(2):298-302. PubMed ID: 11847201
[TBL] [Abstract][Full Text] [Related]
8. Atrial natriuretic peptide modulates sodium and potassium-activated adenosine triphosphatase through a mechanism involving cyclic GMP and cyclic GMP-dependent protein kinase.
Scavone C; Scanlon C; McKee M; Nathanson JA
J Pharmacol Exp Ther; 1995 Mar; 272(3):1036-43. PubMed ID: 7891313
[TBL] [Abstract][Full Text] [Related]
9. Effects of two endogenous Na+,K(+)-ATPase inhibitors, marinobufagenin and ouabain, on isolated rat aorta.
Bagrov AY; Roukoyatkina NI; Pinaev AG; Dmitrieva RI; Fedorova OV
Eur J Pharmacol; 1995 Feb; 274(1-3):151-8. PubMed ID: 7768267
[TBL] [Abstract][Full Text] [Related]
10. Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity.
Fridman AI; Matveev SA; Agalakova NI; Fedorova OV; Lakatta EG; Bagrov AY
J Hypertens; 2002 Jun; 20(6):1189-94. PubMed ID: 12023690
[TBL] [Abstract][Full Text] [Related]
11. Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension.
Fedorova OV; Talan MI; Agalakova NI; Droy-Lefaix MT; Lakatta EG; Bagrov AY
Hypertension; 2003 Mar; 41(3):505-11. PubMed ID: 12623951
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of Na+, K+-ATPase inhibition by atrial natriuretic factor in rat renal medulla.
Bełtowski J; Górny D; Marciniak A
J Physiol Pharmacol; 1998 Jun; 49(2):271-83. PubMed ID: 9670110
[TBL] [Abstract][Full Text] [Related]
13. Endogenous marinobufagenin-like immunoreactive substance. A possible endogenous Na, K-ATPase inhibitor with vasoconstrictor activity.
Bagrov AY; Dmitrieva RI; Fedorova OV; Kazakov GP; Roukoyatkina NI; Shpen VM
Am J Hypertens; 1996 Oct; 9(10 Pt 1):982-90. PubMed ID: 8896650
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide decreases renal medullary Na+, K+-ATPase activity through cyclic GMP-protein kinase G dependent mechanism.
Bełtowski J; Marciniak A; Wójcicka G; Górny D
J Physiol Pharmacol; 2003 Jun; 54(2):191-210. PubMed ID: 12832721
[TBL] [Abstract][Full Text] [Related]
15. Marinobufagenin, an endogenous alpha-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats.
Fedorova OV; Kolodkin NI; Agalakova NI; Lakatta EG; Bagrov AY
Hypertension; 2001 Feb; 37(2 Pt 2):462-6. PubMed ID: 11230319
[TBL] [Abstract][Full Text] [Related]
16. Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.
Chiou S; Vesely DL
Endocrinology; 1995 May; 136(5):2033-9. PubMed ID: 7720651
[TBL] [Abstract][Full Text] [Related]
17. Binding of ouabain and marinobufagenin leads to different structural changes in Na,K-ATPase and depends on the enzyme conformation.
Klimanova EA; Petrushanko IY; Mitkevich VA; Anashkina AA; Orlov SN; Makarov AA; Lopina OD
FEBS Lett; 2015 Sep; 589(19 Pt B):2668-74. PubMed ID: 26297827
[TBL] [Abstract][Full Text] [Related]
18. The opposite effects of cyclic AMP-protein kinase a signal transduction pathway on renal cortical and medullary Na+,K+-ATPase activity.
Bełtowski J; Marciniak A; Wójcicka G; Górny D
J Physiol Pharmacol; 2002 Jun; 53(2):211-31. PubMed ID: 12120897
[TBL] [Abstract][Full Text] [Related]
19. Plasma marinobufagenin-like and ouabain-like immunoreactivity in adrenocorticotropin-treated rats.
Fedorova OV; Anderson DE; Bagrov AY
Am J Hypertens; 1998 Jul; 11(7):796-802. PubMed ID: 9683040
[TBL] [Abstract][Full Text] [Related]
20. Natriuretic effect of bufalin in isolated rat kidneys involves activation of the Na+-K+-ATPase-Src kinase pathway.
Arnaud-Batista FJ; Costa GT; Oliveira IM; Costa PP; Santos CF; Fonteles MC; Uchôa DE; Silveira ER; Cardi BA; Carvalho KM; Amaral LS; Pôças ES; Quintas LE; Noël F; Nascimento NR
Am J Physiol Renal Physiol; 2012 Apr; 302(8):F959-66. PubMed ID: 22237798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
